Systemic therapy

With approximately 1150 new cases annually in Switzerland, urothelial carcinoma of the urinary bladder is one of the most common cancers of older age. Particularly in the metastatic setting, it has become after a long lull in therapy. For example, checkpoint inhibitors are now the established standard of care in the second-line setting, and avelumab was recently approved for maintenance therapy in the first-line setting.